Article Type
Changed
Fri, 10/17/2025 - 10:56

The FDA approved a supplemental new drug application for the JAK inhibitor upadacitinib (Rinvoq, AbbVie) permitting its use in the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.

The updated indication allows for starting upadacitinib before a TNF blocker in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy, the company said in a statement. 

Previously, upadacitinib was indicated only in adults with moderately to severely active ulcerative colitis or Crohn’s disease who had an inadequate response or intolerance to one or more TNF blockers. 

“Ulcerative colitis and Crohn’s disease can impact every aspect of a patient’s life. This label update gives healthcare providers the option to prescribe Rinvoq for patients with moderately to severely active inflammatory bowel disease after the use of one approved systemic therapy if TNF blockers are deemed clinically inadvisable by the prescribing physician,” Kori Wallace, MD, PhD, vice president and global head of immunology clinical development at AbbVie, said in the statement. 

Full prescribing information is available online. 

Wallace is an employee of AbbVie.

A version of this article appeared on Medscape.com . 

Publications
Topics
Sections

The FDA approved a supplemental new drug application for the JAK inhibitor upadacitinib (Rinvoq, AbbVie) permitting its use in the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.

The updated indication allows for starting upadacitinib before a TNF blocker in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy, the company said in a statement. 

Previously, upadacitinib was indicated only in adults with moderately to severely active ulcerative colitis or Crohn’s disease who had an inadequate response or intolerance to one or more TNF blockers. 

“Ulcerative colitis and Crohn’s disease can impact every aspect of a patient’s life. This label update gives healthcare providers the option to prescribe Rinvoq for patients with moderately to severely active inflammatory bowel disease after the use of one approved systemic therapy if TNF blockers are deemed clinically inadvisable by the prescribing physician,” Kori Wallace, MD, PhD, vice president and global head of immunology clinical development at AbbVie, said in the statement. 

Full prescribing information is available online. 

Wallace is an employee of AbbVie.

A version of this article appeared on Medscape.com . 

The FDA approved a supplemental new drug application for the JAK inhibitor upadacitinib (Rinvoq, AbbVie) permitting its use in the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.

The updated indication allows for starting upadacitinib before a TNF blocker in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy, the company said in a statement. 

Previously, upadacitinib was indicated only in adults with moderately to severely active ulcerative colitis or Crohn’s disease who had an inadequate response or intolerance to one or more TNF blockers. 

“Ulcerative colitis and Crohn’s disease can impact every aspect of a patient’s life. This label update gives healthcare providers the option to prescribe Rinvoq for patients with moderately to severely active inflammatory bowel disease after the use of one approved systemic therapy if TNF blockers are deemed clinically inadvisable by the prescribing physician,” Kori Wallace, MD, PhD, vice president and global head of immunology clinical development at AbbVie, said in the statement. 

Full prescribing information is available online. 

Wallace is an employee of AbbVie.

A version of this article appeared on Medscape.com . 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 10/17/2025 - 10:54
Un-Gate On Date
Fri, 10/17/2025 - 10:54
Use ProPublica
CFC Schedule Remove Status
Fri, 10/17/2025 - 10:54
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Fri, 10/17/2025 - 10:54